` GLPG (Galapagos NV) vs DAX Index Comparison - Alpha Spread

GLPG
vs
DAX Index

Over the past 12 months, GLPG has underperformed DAX Index, delivering a return of 1% compared to the DAX Index's 26% growth.

Stocks Performance
GLPG vs DAX Index

Loading

Performance Gap
GLPG vs DAX Index

Loading
GLPG
DAX Index
Difference

Performance By Year
GLPG vs DAX Index

Loading
GLPG
DAX Index
Add Stock

Competitors Performance
Galapagos NV vs Peers

DAX Index
GLPG
ABBV
AMGN
GILD
VRTX
Add Stock

Galapagos NV
Glance View

Market Cap
1.7B EUR
Industry
Biotechnology

Founded in 1999, Galapagos NV emerged from the rich scientific collaboration between the Netherlands and Belgium, initially as a joint venture between the Dutch company Crucell and the Flemish biotech company Tibotec. In its early years, Galapagos carved a niche for itself by focusing on the discovery of novel targets leading to the development of human proteins for medicines. Through its proprietary technological platforms, Galapagos identifies and validates these targets, setting the stage for developing small molecules that inhibit these specific proteins. This unique approach positions the company at the forefront of innovative drug discovery, primarily targeting inflammatory diseases, fibrosis, and other conditions where there is a significant unmet medical need. Revenue for Galapagos is generated through several streams, most notably from strategic partnership deals and potential milestone payments in the biotech sector. The heart of its business model lies in deep collaborations with major pharmaceutical companies like Gilead Sciences, which bolster its financial stability and provide mutual benefits in drug development ventures. Additionally, Galapagos advances its proprietary drug candidates in clinical trials, aiming to bring them to market and secure approval from regulatory bodies. By successfully moving these candidates through clinical development phases, it stands to secure substantial future revenue from both commercialization and licensing deals. With its innovative science-focused strategy, Galapagos continues to propel forward, endeavoring to transform scientific insights into tangible therapeutic advancements.

GLPG Intrinsic Value
24.08 EUR
Overvaluation 6%
Intrinsic Value
Price
Back to Top